Organogenesis Holdings Inc. (ORGO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Organogenesis reported revenue of $564.2M, up 17.0% from $482.0M the year before. Net income was $37.0M (a 6.6% net margin), or $0.15 per diluted share. Gross margin was 75.6% and operating margin was 7.9%. Operating activities generated -$10.3M of cash, leaving -$24.5M of free cash flow. At fiscal year end, Organogenesis held $598.7M in total assets against $164.8M in total liabilities, including $93.7M of cash and equivalents.
Open the full interactive Organogenesis financials → Quarterly statements, key ratios, valuation history and price charts.
Organogenesis Key Stats
| Share Price | $1.21 |
|---|---|
| Market Cap | $155.7M |
| P/E Ratio | 8.1 |
| Revenue YoY Growth | +17.0% |
| 52-Week Range | $1.21 – $6.54 |
| Shares Outstanding | 128.7 million (basic, 2026 Q2) |
Organogenesis Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $338.3M | $468.1M | $450.9M | $433.1M | $482.0M | $564.2M |
| Cost of Goods Sold | — | — | — | — | — | $137.5M |
| Gross Profit | $251.0M | $353.9M | $345.9M | $326.7M | $366.3M | $426.6M |
| Operating Income | $27.4M | $72.9M | $22.3M | $12.5M | -$1.3M | $44.7M |
| Pre-Tax Income | $18.5M | $63.8M | $20.3M | $10.4M | -$2.8M | $47.0M |
| Income Tax | $530,000 | -$31.1M | $4.8M | $5.4M | -$3.7M | $9.9M |
| Net Income | $17.9M | $94.9M | $15.5M | $4.9M | $861,000 | $37.0M |
| Diluted EPS | $0.16 | $0.71 | $0.12 | $0.04 | -$0.01 | $0.15 |
Organogenesis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $150.9M | $225.6M | $37.2M | $43.8M |
| Net Income | $21.6M | $43.7M | -$53.2M | -$96.3M |
| Diluted EPS | $0.11 | $0.34 | -$0.44 | -$0.77 |
Organogenesis Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $113.9M | $102.5M | $103.8M | $135.6M | $93.7M |
| Current Assets | $174.3M | $227.0M | $222.6M | $225.0M | $285.9M | $362.2M |
| Total Assets | $294.5M | $443.3M | $449.4M | $460.0M | $497.9M | $598.7M |
| Current Liabilities | $68.2M | $82.0M | $75.0M | $80.5M | $77.5M | $100.1M |
| Total Long-Term Debt | $70.0M | $74.1M | $71.2M | $66.6M | — | — |
| Total Liabilities | $148.4M | $201.2M | $183.7M | $181.4M | $112.6M | $164.8M |
| Shareholders' Equity | $146.1M | $242.0M | $265.7M | $278.7M | $262.9M | $300.1M |
Organogenesis Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $6.8M | $62.0M | $24.9M | $30.9M | $14.2M | -$10.3M |
| Cash From Investing | -$24.8M | -$31.2M | -$33.9M | -$24.4M | -$10.0M | -$14.2M |
| Cash From Financing | $42.5M | -$1.0M | -$2.2M | -$5.5M | $27.6M | -$17.4M |
| Free Cash Flow | -$14.3M | $30.8M | -$9.0M | $6.6M | $4.2M | -$24.5M |
Figures from Organogenesis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Organogenesis financials page for every line item.
Organogenesis Company Profile
| Ticker | ORGO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Canton, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001661181 |
Frequently Asked Questions
What was Organogenesis' revenue in fiscal 2025?
Organogenesis (ORGO) reported revenue of $564.2M for fiscal 2025.
What is Organogenesis' annual revenue history?
Organogenesis' annual revenue by fiscal year: 2020: $338.3M; 2021: $468.1M; 2022: $450.9M; 2023: $433.1M; 2024: $482.0M; 2025: $564.2M.
What was Organogenesis' net income in fiscal 2025?
Organogenesis reported net income of $37.0M for fiscal 2025.
What was Organogenesis' earnings per share (EPS) in fiscal 2025?
Organogenesis' diluted EPS was $0.15 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Organogenesis generate in fiscal 2025?
Organogenesis generated -$24.5M of free cash flow in fiscal 2025.
What was Organogenesis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Organogenesis reported revenue of $43.8M.
How many shares of Organogenesis are outstanding?
Organogenesis reported a weighted average of 128.7 million basic shares outstanding in 2026 Q2.
What is Organogenesis' market cap?
Based on its latest closing price, Organogenesis (ORGO) has a market capitalization of about $155.7M.
When does Organogenesis' fiscal year end?
Organogenesis' fiscal year end, as registered with the SEC, is December 31.
Where is Organogenesis headquartered?
Organogenesis lists its business address in Canton, Massachusetts in its SEC filings.